Health Regulatory Authority In The US Inspects Sharon Bio-Medicine’s Dehradun Plant

One of the formulation plants at Dehradun in Uttarakhand has been inspected and audited by US Food and Drug Administration (USFDA) officials.

Pharmaceutical company, Sharon Bio-Medicine’s formulation plant in Dehradun was inspected by the US Food and Drug Administration on August 18.

"In the last week one of our formulation plants at Dehradun in Uttarakhand has been inspected and audited by US Food and Drug Administration (USFDA) officials," Sharon Bio-Medicine said in a Bombay Stock Exchange filing. The company’s manufacturing facility at Taloja near Navi Mumbai had been inspected by the USFDA, it added.

Ahmedabad- based Drug Firm Takes Hold of 50-Year-Old Zyg Pharma Ltd
The acquisition will help Torrent Pharmaceuticals strengthen its position in the niche dermatological segment of the developed markets.

"This is our second plant which has been inspected and audited by USFDA officials in the last two months. First plant at Taloja near Navi Mumbai was inspected and audited in the first week of July 2015," the company said.

A warning letter to the firm was issued by the USFDA for failing to pay generic drug user fee by its owner for 3 months starting 2013, saying its Dehradun-based facility would be barred from shipping products to the US if the dues are not cleared.

Source-Medindia

Mumbai- Based Drug Firm Recalls Over 160,000 Cartons of Drugs from the US Market
Recalls have been classified as 'Class-II' by the FDA because using or exposure to the drugs may have caused adverse health consequences in certain individuals

Drug Firm Jubilant Life Sciences Gets ANDA Approval for Generics Mycophenolate Mofetil and Rizatriptan
The Indian drug company, Jubilant Life Sciences, has announced in a statement that it has received final approvals for its generics Mycophenolate Mofetil and Rizatriptan from the FDA.

UK Drug Firm GlaxoSmithKline Announces Africa Investment
GlaxoSmithKline, British pharmaceutical giant, announced a five-year investment programme for sub-Saharan Africa to fuel the company's growth and to serve an area with pressing health needs .